Publication | Closed Access

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast CancerAdjuvant TrastuzumabCancer TreatmentMedicineRadiation Oncology